| Name | Title | Contact Details |
|---|
Tempest Therapeutics is a development-stage biotechnology company advancing small molecule therapeutics that modulate anti-tumor immunity pathways.
XyloCor Therapeutics is a biopharmaceutical company focused on the development of novel gene therapy for unmet needs in advanced coronary artery disease. In the United States, coronary artery disease is a leading cause of death and disability. The Company`s lead product candidate, XC001, is in clinical development to investigate use for patients with refractory angina for which there are no treatment options. XyloCor also has a secondary product, XC002, in discovery stage, being developed for the treatment of patients with cardiac tissue damage from heart attacks. Co founded by Ronald Crystal, MD, and Todd Rosengart, MD, XyloCor has a licensing agreement with Weill Cornell Medicine for the worldwide rights to develop, manufacture and commercialize XC001.
Janux Therapeutics is an innovative biopharmaceutical company developing next-generation therapeutics based on its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to better treat patients suffering from cancer.
AGC Biologics is a leading global Contract Development and Manufacturing Organization (CDMO), with a relentless commitment to deliver the highest standard of service to our clients and partners.
STL now operates the world's largest independent dynamic testing facility for tires, wheels and related automotive components, providing the rubber and automotive industries with dynamic laboratory testing, static and physical testing, fleet testing,